Quince Therapeutics Inc (Quince ), formerly Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and
other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. The company trades on NMS exchange. The company headquarter is located in South San Francisco, United States. The company was established in the 2012.
| Ticker | QNCX |
| Long Name | Quince Therapeutics Inc |
| Short Name | Quince Therapeutics, Inc. |